Doximity (NYSE:DOCS – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Volatility and Risk
Doximity has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
Profitability
This table compares Doximity and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Doximity | 25.48% | 18.06% | 15.40% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Doximity | $644.86 million | 7.39 | $196.05 million | $0.85 | 31.46 |
| Aclarion | $80,000.00 | 86.40 | -$7.23 million | ($7.40) | -0.32 |
Doximity has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
87.2% of Doximity shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 31.8% of Doximity shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Doximity and Aclarion, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Doximity | 4 | 12 | 7 | 2 | 2.28 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Doximity presently has a consensus target price of $32.43, suggesting a potential upside of 21.27%. Aclarion has a consensus target price of $7.50, suggesting a potential upside of 212.50%. Given Aclarion’s higher probable upside, analysts clearly believe Aclarion is more favorable than Doximity.
Summary
Doximity beats Aclarion on 13 of the 15 factors compared between the two stocks.
About Doximity
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
